Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy.
Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:203-210. doi: 10.1016/j.pnpbp.2017.10.005. Epub 2017 Oct 6.
A candidate gene and a genome-wide approach were combined to study the pharmacogenetics of antidepressant response and resistance. Investigated genes were selected on the basis of pleiotropic effect across psychiatric phenotypes in previous genome-wide association studies and involvement in antidepressant response. Three samples with major depressive disorder (total=671) were genotyped for 44 SNPs in 8 candidate genes (CACNA1C, CACNB2, ANK3, GRM7, TCF4, ITIH3, SYNE1, FKBP5). Phenotypes were response/remission after 4weeks of treatment and treatment-resistant depression (TRD). Genome-wide data from STARD were used to replicate findings for response/remission (n=1409) and TRD (n=620). Pathways including the most promising candidate genes were investigated in STARD for involvement in TRD. FKBP5 polymorphisms showed replicated but nominal associations with response, remission or TRD. CACNA1C rs1006737 and rs10848635 were the only polymorphisms that survived multiple-testing correction. In STAR*D the best pathway associated with TRD included CACNA1C (GO:0006942, permutated p=0.15). Machine learning models showed that independent SNPs in this pathway predicted TRD with a mean sensitivity of 0.83 and specificity of 0.56 after 10-fold cross validation repeated 100 times. FKBP5 polymorphisms appear good candidates for inclusion in antidepressant pharmacogenetic tests. Pathways including the CACNA1C gene may be involved in TRD and they may provide the base for developing multi-marker predictors of TRD.
候选基因和全基因组方法相结合,研究抗抑郁药反应和耐药性的药物遗传学。在以前的全基因组关联研究中,基于跨精神表型的多效性效应和参与抗抑郁反应选择研究基因,并对其进行选择。对三种重性抑郁障碍样本(共 671 例)进行了 8 个候选基因(CACNA1C、CACNB2、ANK3、GRM7、TCF4、ITIH3、SYNE1、FKBP5)的 44 个 SNP 基因分型。表型是治疗 4 周后的反应/缓解和治疗抵抗性抑郁症(TRD)。STARD 的全基因组数据用于复制反应/缓解(n=1409)和 TRD(n=620)的发现。STARD 中调查了包括最有希望的候选基因在内的途径,以研究其对 TRD 的影响。FKBP5 多态性与反应、缓解或 TRD 存在重复但名义上的关联。CACNA1C rs1006737 和 rs10848635 是唯一经过多重检验校正的多态性。在 STAR*D 中,与 TRD 最相关的最佳途径包括 CACNA1C(GO:0006942,置换 p=0.15)。机器学习模型显示,该途径中的独立 SNP 可预测 TRD,10 倍交叉验证重复 100 次后的平均敏感度为 0.83,特异性为 0.56。FKBP5 多态性似乎是纳入抗抑郁药遗传测试的良好候选者。包括 CACNA1C 基因的途径可能与 TRD 有关,它们可能为开发 TRD 的多标记预测因子提供基础。